{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:54:25Z","timestamp":1790927665109,"version":"4.1.0"},"reference-count":17,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Dermatol"],"abstract":"<jats:p>&lt;p&gt;Introduction: In the assessment of a psoriasis treatment, traditional endpoints evaluated independently may not fully capture the multidimensional nature of treatment response. Best response to calcipotriol\/betamethasone dipropionate (CAL\/BDP) cream based on polyaphron dispersion (PAD) technology has recently been defined as a restrictive composite endpoint comprising two efficacy outcomes (Physician\u2019s Global Assessment [PGA] 0\u20131 and modified Psoriasis Area and Severity Index [mPASI] &lt;2) and one quality-of-life outcome (Dermatology Life Quality Index [DLQI] 0\u20131). Case Presentation(s): This retrospective case series aims to provide further insights into the demographics and outcomes of patients achieving best response to CAL\/BDP PAD cream based on this newly defined composite endpoint. From the 213 patients with mild-to-moderate psoriasis who received CAL\/BDP PAD cream in the European MC2-01-C7 phase 3 clinical trial (NCT03802344), 7 patients who achieved best response at week 4 and\/or week 8 and had available clinical photographs were evaluated. The mean patient age was 55.0 years (range: 34\u201368), with a mean psoriasis duration of 19.9 years (range: 6.9\u201329.1). Results support the efficacy of CAL\/BDP PAD cream in improving both clinical signs and quality of life. Conclusion: Despite existing variability in key baseline characteristics and long disease duration, all included patients met the novel restrictive composite endpoint after 8 weeks, which reflects complete\/almost complete clearance of psoriasis and no impact on patient quality of life. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000552884","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:00:39Z","timestamp":1787328039000},"page":"684-694","source":"Crossref","is-referenced-by-count":0,"title":["A New Restrictive Composite Endpoint to Assess Best Response in Patients with Mild-to-Moderate Psoriasis Treated with CAL\/BDP PAD Cream: A Case Series"],"prefix":"10.1159","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Andreas","family":"Pinter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-2129","authenticated-orcid":false,"given":"Jordi","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8613-5302","authenticated-orcid":false,"given":"Frank","family":"Freischl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1776116"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01003-0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19330"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2021.5653"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2357618"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1986637"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01060-5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031237"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.022"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.391"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01418-x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/69804"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13089"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00544-6"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03563.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08832.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04525.x"}],"container-title":["Case Reports in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:17:29Z","timestamp":1790925449000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000552884","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.33306426","asserted-by":"subject"}]},"ISSN":["1662-6567"],"issn-type":[{"value":"1662-6567","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}